Overview

Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Status:
Terminated

Trial end date:
2008-11-11

Target enrollment:

Participant gender:

Summary

This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs. the FDC once daily in the morning and formoterol fumarate once in the evening vs. formoterol fumarate twice daily. The study will assess pulmonary function and symptoms in patients with moderate to severe COPD.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Bromides
Formoterol Fumarate